Last reviewed · How we verify
Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the IOP-lowering efficacy of a combination of Travoprost / Timolol maleate, dosed in the morning or in the evening, in patients with open-angle glaucoma or ocular hypertension, who have an insufficiently controlled IOP (mmHg), and are using prostaglandin analogue monotherapy.
Details
| Lead sponsor | Alcon Research |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 36 |
| Start date | 2008-09 |
| Completion | 2011-01 |
Conditions
- Open-angle Glaucoma
- Ocular Hypertension
Interventions
- Travoprost 0.004% / Timolol maleate 0.5%
- Travoprost 0.004% / Timolol maleate 0.5%
Primary outcomes
- Reduction in intraocular pressure — week 4, week 12
Countries
United Kingdom